Premium
Lisdexamfetamine: new second‐line treatment option in ADHD
Author(s) -
Chaplin Steve,
Hayward David
Publication year - 2013
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1112
Subject(s) - methylphenidate , medicine , prodrug , adverse effect , first line , psychiatry , pharmacology , attention deficit hyperactivity disorder
Lisdexamfetamine is a prodrug of dexamfetamine indicated for the treatment of ADHD. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr David Hayward discusses its place in treatment compared with methylphenidate.